title: [Pharmacokinetics interaction among three major active compounds of Shengmai formula in rats].
abstract: To investigate the pharmacokinetic interaction among three major bioactive compounds of Shengmai formula.
  
  
  
  After oral administration of ginsenoside Rg(1), ginsenoside Rb(1) and schisandrin with the same dose(100 mg.kg(-1)) individually or in combination, rat serum samples were extracted, then these three compounds were determined by liquid chromatography-mass spectrometry(LC-MS). The pharmacokinetic parameters of three compounds in single or combination form were calculated by WinNonLinu6.0 using non-compartment model.
  
  
  
  Compared with single drug group, the peak concentration of ginsenoside Rg(1) in combined group increased from(0.476 ±0.238) μg.ml(-1) to (1.946 ±1.432) μg.ml(-1), AUC(0-∞) increased from(0.523 ±0.238) μg.h.ml(-1) to (1.908 ±1.319) μg.h.ml(-1), CL decreased from(226311 ± 96819) ml.h(-1).kg(-1) to(90650 ±73684) ml.h(-1).kg(-1) and Vd decreased from(317110 ±154009) ml.kg(-1) to(130967 ±78306) ml.kg(-1). While the pharmacokinetic parameters of ginsenoside Rb(1) and schisandrin showed no significant change.
  
  
  
  Combined oral administration of three compounds of Shengmai formula can improve the bioavailability of ginsenoside RgRg(1), however it does not change the pharmacokinetic behavior of ginsenoside RbRg(1) and schisandrin.
authors.affiliation: Institute of Pharmaceutical Informatics, Zhejiang University, Hangzhou 310058, China.
authors.forename: Wen-jing
authors.initials: WJ
authors.lastname: Guo
authors.forename: Qing
authors.initials: Q
authors.lastname: Shao
authors.forename: Yu-feng
authors.initials: YF
authors.lastname: Zhang
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Fan
mesh_terms: D000818:Animals; D001682:Biological Availability; D002853:Chromatography, Liquid; D034242:Cyclooctanes / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D004357:Drug Synergism; D036145:Ginsenosides / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D017705:Lignans / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D011083:Polycyclic Compounds / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D053719:Tandem Mass Spectrometry
chemical_list: D034242:Cyclooctanes; D036145:Ginsenosides; D017705:Lignans; D011083:Polycyclic Compounds; C011105:schizandrin